Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

October 30, 2019

Study Completion Date

January 1, 2020

Conditions
Retinitis PigmentosaInherited Retinal Dystrophy
Interventions
BIOLOGICAL

Wharton's jelly derived mesenchymal stem cell

The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .

Trial Locations (2)

06312

Ankara University Biotechnology Institute, Ankara

Umut Arslan, Ankara

All Listed Sponsors
lead

Ankara Universitesi Teknokent

OTHER

NCT04224207 - Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells | Biotech Hunter | Biotech Hunter